Seaport Therapeutics (NASDAQ:SPTX) Issues Quarterly Earnings Results

Seaport Therapeutics (NASDAQ:SPTX) released its earnings results on Monday. The company reported ($1.78) earnings per share (EPS) for the quarter, FiscalAI reports.

Seaport Therapeutics Price Performance

Shares of NASDAQ:SPTX opened at $20.46 on Monday. The stock has a market capitalization of $1.10 billion and a P/E ratio of -1.98. Seaport Therapeutics has a 52-week low of $14.85 and a 52-week high of $23.00. The firm has a fifty day moving average of $19.30.

Insider Activity at Seaport Therapeutics

In other Seaport Therapeutics news, Director Robert J. Hombach bought 13,000 shares of the company’s stock in a transaction that occurred on Monday, June 22nd. The stock was purchased at an average cost of $18.14 per share, for a total transaction of $235,820.00. Following the completion of the purchase, the director owned 13,000 shares of the company’s stock, valued at $235,820. This trade represents a ∞ increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink.

Analysts Set New Price Targets

SPTX has been the subject of a number of analyst reports. BNP Paribas Exane lowered Seaport Therapeutics to a “market perform” rating in a research report on Tuesday, May 26th. Citigroup began coverage on shares of Seaport Therapeutics in a research note on Tuesday, May 26th. They issued a “buy” rating and a $35.00 price target for the company. HC Wainwright began coverage on Seaport Therapeutics in a research report on Wednesday, July 15th. They set a “buy” rating and a $50.00 target price on the stock. Seaport Research Partners set a $50.00 target price on shares of Seaport Therapeutics in a report on Wednesday, July 15th. Finally, Stifel Nicolaus assumed coverage on Seaport Therapeutics in a research note on Tuesday, May 26th. They issued a “buy” rating and a $30.00 price target on the stock. Five investment analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the stock currently has an average rating of “Hold” and a consensus target price of $38.40.

Seaport Therapeutics, Inc is a healthcare company in the Pharmaceuticals industry.